Publications
Recent high-impact publications from Rogel Cancer Center members.
|
|
Publications from members of the Cancer Biology, Cancer Genetics, Cancer Hematopoiesis & Immunology, and Developmental Therapeutics programs |
|
Shukla S, Ying W, Gray F, Yao Y, Simes ML, Zhao Q, Miao H, Cho HJ, González-Alonso P, Winkler A, Lund G, Purohit T, Kim E, Zhang X, Ray JM, He S, Nikolaidis C, Ndoj J, Wang J, Jaremko Ł, Jaremko M, Ryan RJH, Guzman ML, Grembecka J, Cierpicki T. Small-molecule inhibitors targeting Polycomb repressive complex 1 RING domain. Nat Chem Biol. (2021) PMID: 34155404; PMCID: PMC8238916.
Du W, Hua F, Li X, Zhang J, Li S, Wang W, Zhou J, Wang W, Liao P, Yan Y, Li G, Wei S, Grove S, Vatan L, Zgodzinski W, Majewski M, Wallner G, Chen H, Kryczek I, Fang JY, Zou W. Loss of optineurin drives cancer immune evasion via palmitoylation-dependent IFNGR1 lysosomal sorting and degradation. Cancer Discov. (2021) PMID: 33627378; PMCID: PMC8292167.
Yu L, Myers G, Ku CJ, Schneider E, Wang Y, Singh SA, Jearawiriyapaisarn N, White A, Moriguchi T, Khoriaty R, Yamamoto M, Rosenfeld M, Pedron J, Bushweller JH, Lim KC, Engel JD. An erythroid to myeloid cell fate conversion is elicited by LSD1 inactivation. Blood. (2021) PMID: 34324630.
Luan X, Yuan H, Song Y, Hu H, Wen B, He M, Zhang H, Li Y, Li F, Shu P, Burnett JP, Truchan N, Palmisano M, Pai MP, Zhou S, Gao W, Sun D. Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation. Biomaterials. (2021) PMID: 34144373.
Kremer DM, Nelson BS, Lin L, Yarosz EL, Halbrook CJ, Kerk SA, Sajjakulnukit P, Myers A, Thurston G, Hou SW, Carpenter ES, Andren AC, Nwosu ZC, Cusmano N, Wisner S, Mbah NE, Shan M, Das NK, Magnuson B, Little AC, Savani MR, Ramos J, Gao T, Sastra SA, Palermo CF, Badgley MA, Zhang L, Asara JM, McBrayer SK, Pasca di Magliano M, Crawford HC, Shah YM, Olive KP, Lyssiotis CA. GOT1 inhibition promotes pancreatic cancer cell death by ferroptosis. Nat Commun. (2021) PMID: 34381026; PMCID: PMC8357841.
|
|
|
Co-senior study author
Tomasz Cierpicki
|
|
“This work demonstrates that directly targeting the activity of PRC1 is indeed feasible and could lay the groundwork for the development of new pharmaceutical agents for leukemia and possibly other cancers.” - Tomasz Cierpicki, Ph.D.
|
|
|
|
TRANSLATIONAL AND CLINICAL RESEARCH |
|
Publications from members of the Translational and Clinical Research Program. |
|
Nielsen TO, Leung SCY, Rimm DL, Dodson A, Acs B, Badve S, Denkert C, Ellis MJ, Fineberg S, Flowers M, Kreipe HH, Laenkholm AV, Pan H, Penault-Llorca FM, Polley MY, Salgado R, Smith IE, Sugie T, Bartlett JMS, McShane LM, Dowsett M, Hayes DF. Assessment of Ki67 in breast cancer: updated recommendations from the international Ki67 in breast cancer working group. J Natl Cancer Inst. (2021) PMID: 33369635.
Alva AS, Mangat PK, Garrett-Mayer E, Halabi S, Hansra D, Calfa CJ, Khalil MF, Ahn ER, Cannon TL, Crilley P, Fisher JG, Haslem DS, Shrestha S, Antonelli KR, Butler NL, Warren SL, Rygiel AL, Ranasinghe S, Bruinooge SS, Schilsky RL. Pembrolizumab in patients with metastatic breast cancer with high tumor mutational burden: results from the targeted agent and profiling utilization registry (TAPUR) study. J Clin Oncol. (2021) PMID: 33844595.
|
|
|
Co-senior study author
Ajjai S. Alva, M.D.
|
|
“When it comes to a biomarker to tell us which patients will respond best to immunotherapy, we still have not found the perfect marker, the holy grail — but we have found a very good candidate biomarker in high tumor mutational burden.” - Ajjai S. Alva, M.D.
|
|
|
|
We want to hear your feedback!
|
|
Please forward this message to your colleagues.
|
|
|
|
|
|
|
